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Acute cerebral ischemia is a major cause of mortality and disability worldwide, but no successful pharmacotherapy 
has been established that can benefit patients beyond the time 
window of thrombolysis with recombinant tissue-type plas-
minogen activator (tPA).1 Because of risks related to hemor-
rhage, this window is within 3 to 4.5 hours after the onset of 
symptoms.2 The tPA has also shown neurotoxicity in experi-
mental models of cerebral ischemia.3 Therefore, a combina-
tion treatment that would reduce the deleterious effects of tPA, 
while maintaining the benefits of recanalization, might extend 
the usability and efficacy of tPA.
Fingolimod (FTY720, Gilenya) is a sphingosine analog 
that, when phosphorylated, acts on sphingosine1-phosphate 
receptors, regulating cellular and physiological mechanisms, 
including proliferation, apoptosis, adhesion, migration, dif-
ferentiation/morphogenesis, inflammation, or blood–brain 
barrier (BBB) integrity.4–6 Fingolimod has emerged as a 
new treatment for multiple sclerosis.7,8 The effectiveness of 
fingolimod has also been shown by several groups in rodent 
models of ischemic brain injury.9–12 These studies suggest that 
antiinflammatory mechanisms and vasculoprotection possibly 
underlie the beneficial effects of fingolimod after stroke.12 We 
therefore hypothesized that combining fingolimod with tPA 
might reduce hemorrhagic transformation associated with 
delayed administration of tPA.
In this study, we evaluated the effect of fingolimod in a 
mouse model of thromboembolic stroke, in which the benefi-
cial effect of tPA-induced reperfusion and hemorrhagic trans-
formation associated with delayed administration are similar 
to those occurring in humans.
Material and Methods
Animals
C57BL/6 male mice (25–30 g, Charles River Laboratory) were 
maintained on a 12/12 hours light/dark cycle and fed ad libitum. 
Experiments were conducted according to protocols approved by the 
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Animal Research Committee of Massachusetts General Hospital and 
NIH guide for the Care and Use of Laboratory Animals.
Experimental Groups
Three cohorts were studied (Figure I in the online-only Data 
Supplement): (1) middle cerebral artery occlusion (MCAO) not 
treated with tPA (permanent occlusion); in this group, animals were 
treated (i.p.) with 0.5 mg/kg fingolimod or saline 45 minutes, 24 
and 48 hours after occlusion. (2) MCAO+early tPA, in which tPA 
was administered intravenously 30 minutes after thrombin injec-
tion (transient occlusion); in this group, animals received fingoli-
mod or saline 30 minutes (together with tPA), 24 and 48 hours after 
occlusion. (3) MCAO+delayed tPA, in which tPA was administered 
intravenously 3 hours after thrombin injection (transient occlu-
sion); fingolimod or saline was administered 3 hours (together with 
tPA), 24 and 48 hours after occlusion.
Fingolimod and phosphofingolimod (generous gifts from Dr Volker 
Brinkmann, Novartis Institutes for Biomedical Research, Basel) were 
dissolved in saline and stored at 4°C for <48 hours.
Middle Cerebral Artery Occlusion
Experimental ischemia was carried out as described in References 
13,14 (see the online-only Data Supplement for details). Isoflurane-
anesthetized mice were placed in a stereotaxic frame, the skin be-
tween the right ear and eye was cut, the temporal muscle retracted, a 
craniotomy was performed over the artery bifurcation, the meninges 
were cut, and the middle cerebral artery (MCA), with its parietal and 
frontal branches, was exposed.
A micropipette (tip size: 30–50 µm), filled with 2 UI/μL mouse α-
thrombin (Hematologic Technologies Inc) dissolved in 18% glycerol/
saline, was placed in a micromanipulator and 0.5 μL of thrombin 
solution or vehicle was injected into the lumen of the artery bifurca-
tion to induce the formation of a clot. The micropipette was removed 
15 minutes later, when the clot had stabilized. Artery occlusion 
was considered successful when Laser Speckle Flowmetry showed 
a rapid and drastic fall of brain perfusion that remained stable dur-
ing 80 minutes (mean reduction of 70% to 80%; Figure IIA in the 
online-only Data Supplement). To induce reperfusion, tPA (10 mg/
kg; Alteplase, Activase) was administered i.v. (200 µL, 10% bolus, 
90% perfusion during 40 minutes), 30 minutes (early recanalization), 
or 3 hours (delayed recanalization) after the injection of thrombin. In 
mice with early recanalization, we defined effective reperfusion when 
blood flow recovered to at least 75% of basal values (Figure IIB in the 
online-only Data Supplement).
Assessment of Lesion Volume and Histology
Assessment of lesion volume and histology is described in the online-
only Data Supplement.
Neurological Deficit Evaluation
Neurological deficit was evaluated after ischemia using the grid and 
cylinder tests, described in the online-only Data Supplement.
Quantitative Evaluation of Evans Blue 
Extravasation
To evaluate the effect of fingolimod on blood-barrier damage Evans 
Blue extravasation was determined as described in the online-only 
Data Supplement.
Absolute Cerebral Blood Flow Measurement
Absolute cerebral blood flow measurement details are provided in the 
online-only Data Supplement.
In Vitro tPA Activity Analysis
In vitro interaction assay between tPA activity and fingolimod or 
P-fingolimod is described in the online-only Data Supplement.
Statistical Analysis
Mice were randomly allocated; treatment groups were coded with tail 
marks to assess infarct, hemorrhage area, and neurological deficit in 
a blinded fashion. The number of mice in each group was based on 
power analysis assuming a treatment effect of 30% and an SD of 25%. 
Total number of mice included and mortality during and after surgery 
are summarized in Table I in the online-only Data Supplement.
Data are expressed as mean±SD. For infarct, hemorrhage volumes, 
and Evans Blue extravasation, statistical difference between groups 
was calculated by analysis of variance. Statistical significance was 
evaluated for the grid test using a 2-way ANOVA. Statistical signifi-
cance was evaluated in the cylinder test using 1-way ANOVA. P<0.05 
was considered significant.
Results
Effect of Thrombin and tPA Administration on 
Cerebral Blood Flow
Blood pressure and blood gases were stable in all groups 
under both basal and ischemic conditions (Table). No signifi-
cant differences in these parameters were observed between 
treated and nontreated mice.
In all groups, local injection of thrombin into the MCA 
caused an immediate drop (to ≈10% of baseline) of cerebral 
blood flow. In animals not treated with tPA (permanent occlu-
sion), the occlusion was stable during 80 minutes (as assessed 
by laser speckle flowmetry; Figure 1A) and for at least 4 hours 
(assessed by [14C]iodoantipyrine autoradiography in a sepa-
rate cohort of 4 mice; Figure 1B).
Treatment with tPA 30 minutes after thrombin injection 
induced a gradual reperfusion starting around 30 minutes 
after its administration (Figure 1A). No significant differences 
in reperfusion time were observed between animals treated 
and nontreated with fingolimod. In mice receiving tPA after 
Table. Physiological Parameters 
Thrombin Thrombin+tPA 30 Minutes Thrombin+tPA 3 Hours
Saline FTY720 Saline FTY720 Saline FTY720
Blood pressure (mm Hg) 84.3±6.0 86.1±7.3 86.0±7.3 86.9±7.0 85.7±7.7 82.7±5.0
pH (preischemia) 7.38±0.07 7.39±0.06 7.37±0.08 7.38±0.07 7.36±0.06 7.35±0.08
Pco2 (preischemia, mm Hg) 30.8±4.8 31.0±7.6 35.4±7.7 34.5±6.0 36.0±7.2 37.2±8.1
Po2 (preischemia, mm Hg) 142.7±35.5 146.2±23.3 160.3±34.5 131.7±31.5 133.9±26.3 173.7±25.9
pH (postischemia) 7.39±0.08 7.33±0.05 7.35±0.09 7.32±0.09 7.25±0.12 7.25±0.11
Pco2 (postischemia, mm Hg) 43.7±12.0 45.8±12.2 51.1±14.5 49.4±11.6 48.4±12.9 52.2±15.5
Po2 (postischemia, mm Hg) 132.2±38.6 119.3±38.4 142.4±37.1 109.8±34.4 115.7±30.4 145.8±14.6




 http://ahajournals.org by on February 2, 2021
Campos et al  Fingolimod Prevents Hemorrhagic Transformation   507
3 hours, the cerebral flow was only measured during the first 
80 minutes of the procedure. The occlusion was stable during 
this period.
The effectiveness of reperfusion in mice with transient 
occlusion (see Material and Methods) was confirmed by 
[14C]iodoantipyrine autoradiography. [14C]iodoantipyrine 
autoradiography of brains obtained 4 hours after tPA 
administration confirmed that the clot was completely 
dissolved in both transient ischemic groups.
In the sham group, local administration of thrombin vehi-
cle (18% glycerol) did not alter cerebral blood flow. Mice 
in which baseline cerebral flow was altered as result of the 
craniotomy were not included in the study (Table I in the 
online-only Data Supplement). No persistent cortical spread-
ing depression events were observed after thrombin injection 
in any of the 3 groups studied.
Effect of Fingolimod on Infarct Volume and 
Neuronal Deficit
Permanent occlusion caused a cortical infarct of 27.3±6.1 mm3 
after 3 days. Ischemia was associated with neurological defi-
cits evaluated using the cylinder and grid walking tests on day 
3. In the absence of tPA treatment, infarct volume was signifi-
cantly reduced (17.5±9.1 mm3, P<0.05) when animals received 
3 injections of fingolimod, 45 minutes, 24 and 48 hours after 
thrombin (Figure 2). Reduction of infarct volume by fingoli-
mod was paralleled by better functional outcome (Figure 3).
Early vessel recanalization with tPA reduced infarct volume 
(18.0±5.5 mm3) and improved functional outcome, compared 
with the permanent ischemic group. Fingolimod administered 
in combination with tPA, and 24 and 48 hours after occlusion 
further improved the neuronal deficit in both behavioral tests, 
but did not decrease lesion volume beyond the effect of tPA 
alone (15.7±6.7 mm3).
Figure 1. A, Analysis of cerebral blood flow by laser speckle 
flowmetry (LSF) in the sham group (18% glycerol injection), in 
animals receiving thrombin injection (ischemia) and animals with 
early tissue plasminogen activator (tPA)-induced recanalization 
(ischemia+tPA). Cerebral blood flow is expressed as percentage 
of basal level. B, Regional cerebral blood flood using [14C]iodoan-
tipyrine autoradiography was performed 45 minutes after  
18% glycerol injection (sham, n=2); 45 minutes (n=2) or 240 
minutes (n=4) after MCA occlusion (note that the ischemic area 
extends beyond the territory of the occluded MCA branch,  
probably because of the occurrence of cortical spreading 
depression/periinfarct depolarization); 4 hours after tPA injection 
in mice undergoing early (30 minutes, n=2) or late (180 minutes, 
n=2) tPA recanalization.
Figure 2. A, Representative Hematoxylin and Eosin (H&E)-
stained sections illustrating the effect of vehicle or fingolimod 
(0.5 mg/kg FTY720) on infarct volume in animals with permanent 
occlusion, early recanalization (tissue plasminogen activator [tPA] 
30 minutes after occlusion) and delayed recanalization (tPA 3 
hours after occlusion). B, Infarct volumes were measured 3 days 
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Delayed administration of tPA had no beneficial effect on 
infarct (29.0±4.7 mm3) and neuronal deficit. Both parameters 
were similar to those seen in animals with permanent occlu-
sion. Administration of fingolimod in combination with tPA 
and 24 and 48 hours after occlusion reduced infarct volume 
(22.0±5.9 mm3, P<0.05), and improved both functional out-
come measures.
Effect of Fingolimod on Hemorrhagic 
Transformation and Blood Barrier Breakdown
Permanent occlusion induced by thrombin and early recana-
lization were associated with only minor hemorrhages in the 
ischemic region at 3 days (total volume: 0.27±0.33 mm3 and 
0.17±0.38 mm3 in the permanent and 30 minutes tPA groups). 
No significant difference was observed between groups. 
Fingolimod treatment did not affect hemorrhage volume in 
either group (Figure 4).
Delayed recanalization caused a significant increase in 
hemorrhage volume (1.10±0.62 mm3) compared with animals 
not treated with tPA (P<0.05) and animals treated with tPA 30 
minutes (P<0.05) after occlusion. Hemorrhagic transformation 
was significantly reduced (0.32±0.44 mm3) when tPA was 
administered in combination with fingolimod (P<0.05). The 
same effects were observed after normalization of these data 
by infarct volumes.
Figure 3. Effect of vehicle and fingolimod (FTY720, 0.5 mg/kg) 
on functional deficit, evaluated by the grid-walking test in the 3 
experimental groups tested. Panels A and B show the percent-
age of footslips for the left and right forepaws. The grid-walking 
test was performed 3 days after occlusion. C, Shows the effect 
of vehicle and fingolimod (FTY720, 0.5 mg/kg) on functional defi-
cit, evaluated by the cylinder test in the 3 experimental groups 
tested. This test was performed before surgery (baseline) and 3 
days after occlusion. Animals treated with FTY720 show a behav-
ior close to baseline. Data are means±SD; n=9 to 10; *P<0.05.
Figure 4. A, Representative 3, 3′-diaminobenzidine (DAB)-stained 
sections illustrating the effect of vehicle or fingolimod (0.5 mg/kg 
FTY720) on hemorrhage volume in animals with permanent occlu-
sion, and animals with early or delayed recanalization. B, The 
volume of hemorrhages (small arrows in A) was analyzed 3 days 
after occlusion. Panel C represents the ischemic region normal-
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To further examine the effect of fingolimod on vascular 
integrity, we examined Evans Blue extravasation 24 hours 
after occlusion in mice receiving delayed tPA (Figure 5). We 
found that tPA increased Evans Blue leakage in the ipsilateral 
region (5.6±1.4 ng Evans Blue/mg tissue) compared with 
the contralateral region (1.8±2.1 ng Evans Blue/mg tissue). 
The ipsilateral increase was not observed when tPA was 
administered in combination with fingolimod (2.2±1.6 ng 
Evans Blue/mg tissue, ipsilateral region, P<0.05).
The extent of Evans Blue leakage 3 and 48 hours after tPA 
administration was similar to that observed at 24 hours (data 
not shown), and the effect of fingolimod was only investigated 
at 24 hours.
To demonstrate that the increased Evans Blue leakage was 
caused by tPA and was not because of ischemic damage or 
reperfusion injury, we assessed Evans Blue leakage in mice 
with permanent thrombin-induced occlusion, and in mice 
in which transient occlusion (3 hours) was induced using a 
vessel clip15; but we did not observe an ipsilateral increase 
in Evans Blue extravasation, and therefore did not study the 
effect of fingolimod in either cohort (Figure III in the online-
only Data Supplement). No differences in the pattern of Evans 
Blue leakage were observed after normalizing these data for 
infarct volume.
In Vitro Analysis Interaction of Fingolimod/P-
Fingolimod and tPA Activity
In order to expand on the observation that fingolimod treat-
ment did not affect the reperfusion time course of thrombolytic 
treatment compared with vehicle group (Figure 1), we used an 
in vitro assay to confirm that fingolimod or P-fingolimod did 
not interfere with the enzymatic activity of tPA. Fingolimod 
and P-fingolimod, tested in a range of concentrations between 
0.01 µmol/L and 100 µmol/L, did not modify the activity of 
tPA, at variance with leupeptin, used as a positive control 
(Figure IV in the online-only Data Supplement).
Discussion
This study shows that fingolimod attenuates the neurological 
deficit and reduces infarct volume in a model of thrombo-
embolic MCA occlusion. In this model, in combination with 
thrombolytic therapy, fingolimod improves the neurological 
outcome with early tPA administration, whereas with delayed 
administration of tPA, fingolimod both improves neurological 
outcome and reduces the infarct volume.
Fingomolid has been recently suggested to be a potential 
new treatment for ischemic brain injury, based on several stud-
ies using rodent models of brain ischemia9–12 (1 study, how-
ever, failed to detect an effect,16 suggesting variations possibly 
because of experimental conditions). When protective effects 
by fingolimod were observed, the mechanisms of action were 
not clearly established. Thus, when fingolimod was tested in 
a rat model of transient ischemia by filament occlusion of the 
MCA, it reduced neuronal injury and improved behavior by 
activation of Akt (protein kinase B) and ERK (extracellular 
 signal-regulated kinase) via S1P
1
 receptors, preventing neuronal 
apoptosis.10 In a mouse study, the protective efficacy of fingoli-
mod was associated with a reduction of inflammatory response 
and a direct neuroprotective effect mediated by inhibition of 
apoptotic death, but preservation of BBB was not observed.9 
We have recently described that in a transient mouse model, fin-
golimod reduced infarct size, neurological deficit, and edema.12 
This protective effect was accompanied by decreased inflam-
mation. However, at variance with the neuroprotective effect 
previously described,9,10 fingolimod did not protect primary 
neurons against glutamate excitotoxicity or hydrogen peroxide, 
but it decreased intercellular adhesion molecule 1 (ICAM-1) 
expression in brain endothelial cells stimulated by tumor necro-
sis factor-α. The findings of the later study suggest that anti-
inflammatory mechanisms, and possibly vasculoprotection, 
rather than direct effects on neurons, are the most plausible 
mechanisms that underlie the beneficial effects of fingolimod.12
In the 3 treatment paradigms used in the present study, fin-
golimod improved neurological deficit, but did not achieve 
a significant reduction of infarct volume when administered 
in combination with tPA 30 minutes after occlusion (Figure 
2). Previous clinical studies have observed that tPA treatment 
administered within 3 hours of symptom onset decreases the 
neuroinflammation that follows stroke.17 Although further 
studies are necessary to confirm this hypothesis, we speculate 
that the reduction of inflammatory response induced by early 
tPA administration might have masked the beneficial effect of 
fingolimod on infarct size.
Figure 5. A, Effect of fingolimod (0.5 mg/kg FTY720) on Evans 
Blue extravasation in animals with delayed recanalization deter-
mined in contralateral and ipsilateral hemisphere of control and 
treated group. B, Shows Evans Blue extravasation in ischemic 
region normalized for infarct volume. Evans Blue extravasation 
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Vasculoprotection and preservation of BBB integrity are 
other important processes associated with the activation of 
S1P receptors,18,19 and have been implicated in the effects of 
fingolimod in studies unrelated to stroke.20 S1P receptor acti-
vation stimulates the recruitment of endothelial proteins that 
form adherens junctions, thereby creating a tighter contact 
between endothelial cells, enhancing BBB integrity.20
Early tPA administration is the optimal therapeutic strategy 
to rescue still viable ischemic tissue, and to improve the 
outcome in patients with acute ischemic stroke. But studies 
based on magnetic resonance perfusion/diffusion imaging 
(mismatch concept)21 suggest that there might be patients 
who could benefit from thrombolysis beyond 3 hours, 
even if they present a higher risk of BBB breakdown and 
hemorrhagic transformation. In agreement with these clinical 
data and also with previous experimental studies in rats and 
mice, we observed that tPA administered 30 minutes after 
thrombin injection (early administration) reduced ischemic 
injury without BBB damage, whereas BBB breakdown and 
hemorrhagic transformation appeared when tPA was given 3 
hours after occlusion (delayed administration).
Of note, the dose of 10 mg/kg tPA used in the current study 
is higher than the clinical dose (0.9 mg/kg). The fibrinolytic 
system in rodents has been known for 30 years to be about 10 
times less sensitive to tPA than in humans.22 The vast major-
ity of stroke studies in rodents have therefore been performed 
with 10 mg/kg tPA. In our study, significant hemorrhages were 
not seen with early tPA. We therefore assume that the hem-
orrhages we observed were the consequence of the delayed 
administration rather than of the high dose of tPA, and we 
believe that fingolimod-induced prevention of BBB damage 
caused by delayed tPA might indeed be clinically significant. 
Similarly, mice were treated with rather high doses of fingo-
limod (0.5 mg/kg bodyweight/d), but it is a dose commonly 
used to treat mice with experimental autoimmune encephalo-
myelitis (a model of multiple sclerosis).23,24
It is possible that reduced hemorrhagic transformation and 
Evans Blue extravasation could be the mere consequence 
of reduced infarct volume in fingolimod-treated mice after 
delayed rtPA, as a direct effect of fingolimod on BBB damage 
was not demonstrated. But this is unlikely, as normalized data 
per infarct volume (Figures 4 and 5) or lack of Evans Blue 
leakage in mice with permanent occlusion or mice with tran-
sient occlusion (3 hours) induced using a vessel clip (Figure 
III in the online-only Data Supplement) suggest that BBB 
damage was not associated with infarct size and was mediated 
by delayed tPA administration, confirming the vasculoprotec-
tive effect of fingolimod.
Several treatments, some promising, have been tested in 
combination with tPA (see25 for review) to reduce its neurotox-
icity, risk of hemorrhage, and reperfusion injury, or to increase 
neuroprotection and increase therapeutic time window. One of 
the advantages of fingolimod with respect to other treatments 
is that, in addition to reducing the risk of hemorrhage, fingo-
limod is itself protective, which is likely to synergize with the 
benefits of thrombolytic therapy, as we have observed in our 
study.
In conclusion, in this study, we have confirmed the protec-
tive efficacy of fingolimod as a treatment against ischemic 
stroke in a novel model thromboembolic occlusion model, and 
we have shown the potential applicability of this treatment in 
combination with tPA to reduce the risk of brain hemorrhage.
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